AI Article Synopsis
- Researchers are studying how immune checkpoint blockade helps treat cancers like lung cancer, but there's still a lot we don’t understand about how tumor cells interact with their environment.
- They are focusing on a protein called STAT3 that makes tumors resistant to some treatments.
- The review discusses how understanding STAT3's role in the immune system could help in finding new ways to predict how well patients will respond to immunotherapy and improve its effectiveness.
Article Abstract
Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888808 | PMC |
| http://dx.doi.org/10.1177/1758835918763744 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!